Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers.
Meropenem is a broad-spectrum carbapenem antibacterial agent. In order to optimize levels in plasma relative to the MICs, the ideal dose level and dosage regimen need to be determined. The pharmacokinetics of meropenem were studied in two groups, each comprising eight healthy volunteers who received the following doses: 500 mg as an intravenous infusion over 30 min three times a day (t.i.d.) versus a 250-mg loading dose followed by a 1,500 mg continuous infusion over 24 h for group A and 1,000 mg as an intravenous infusion over 30 min t.i.d. versus a 500-mg loading dose followed by a 3,000-mg continuous infusion over 24 h for group B. Meropenem concentrations in plasma and urine were determined by liquid chromatography-mass spectrometry/mass spectrometry and high-performance liquid chromatography with UV detection, respectively. Pharmacokinetic calculations were done by use of a two-compartment open model, and the data were extrapolated by Monte Carlo simulations for 10,000 simulated subjects for pharmacodynamic evaluation. There were no significant differences in total clearance and renal clearance between group A and group B or between the intermittent treatment and the continuous infusion. The analyses of the probability of target attainment by MIC for the high- and low-dose continuous infusions were robust up to MICs of 4 mg/liter and 2 mg/liter, respectively. The corresponding values for intermittent infusions were only 0.5 mg/liter and 0.25 mg/liter. When these observations were correlated with MICs obtained from the MYSTIC database, intermittent infusion results in adequate activity against two of the most common nosocomially acquired pathogens, Klebsiella pneumoniae and Enterobacter cloacae. However, against Pseudomonas aeruginosa, the evaluation shows a clear advantage of high-dose therapy administered as a continuous infusion. We believe that in the empirical therapy situation, the continuous-infusion mode of administration is most worth the extra efforts. We conclude that clinical trials for evaluation of the continuous infusions of meropenem in critically ill patients are warranted.
Krueger
Wolfgang A
WA
IBMP-Institute for Biomedical and Pharmaceutical Research, Paul-Ehrlich-Str. 19, D-90562 Nürnberg-Heroldsberg, Germany.
Bulitta
Jurgen
J
Kinzig-Schippers
Martina
M
Landersdorfer
Cornelia
C
Holzgrabe
Ulrike
U
Naber
Kurt G
KG
Drusano
George L
GL
Sörgel
Fritz
F
D000293:Adolescent; D000328:Adult; D002851:Chromatography, High Pressure Liquid; D003198:Computer Simulation; D018592:Cross-Over Studies; D016208:Databases, Factual; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D013058:Mass Spectrometry; D000077731:Meropenem; D009010:Monte Carlo Method; D013056:Spectrophotometry, Ultraviolet; D013845:Thienamycins / Q000008:administration & dosage* / Q000493:pharmacokinetics* / Q000633:toxicity
D013845:Thienamycins; D000077731:Meropenem